Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?

GÜNDOĞDU, HASAN; Asa, Sertac; ARPA, Medeni; Eren Kupik, Gülnihan; kupik, osman; Bozkurt, Mehmet

doi:10.4999/uhod.204173

Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?

Osman KUPIK, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Rize, Türkiye)

Mehmet BOZKURT, (Sağlık Bilimleri Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye)

SERTAÇ ASA, (İstanbul Üniversitesi-Cerrahpaşa, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye)

Gulnihan EREN, (Sıtkı Koçman Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Muğla, Türkiye)

Hasan GUNDOGDU, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Radyoloji Anabilim Dalı, Rize, Türkiye)

Medeni ARPA (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Rize, Türkiye)

Uluslararası Hematoloji-Onkoloji Dergisi

10 2

Yıl: 2020 Cilt: 30 Sayı: 3 Sayfa Aralığı: 162 - 170 Metin Dili: İngilizce DOI: 10.4999/uhod.204173 İndeks Tarihi: 20-12-2020

Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?

Öz:

To determine the relationship between 18F FDG PET/CT parameters of the primary tumor/nodal metastasis/distant metastasis andoverall survival (OS) of patients with newly diagnosed non-small cell lung cancer (NSCLC). Data from 159 patients with newly diagnosedNSCLC who underwent pretreatment 18F FDG PET/CT were analyzed. The SUVmax, SUVmean, the metabolic tumor volume(MTV), and total lesion glycolysis (TLG) of the primary tumor, lymph node metastasis, and distant metastasis were measured. The totalMTV and total TLG were calculated. The optimal cut-off values of the 18F FDG PET/CT parameters were determined using receiveroperating characteristics curve analysis. Kaplan-Meier curves were used to determine OS. There were a total of 101 deaths duringthe follow-up (range, 3.7-54.2 months). The median OS was 26.4 months for the entire group, 11.8 months for patients with metastasis,and 41 months for patients with no metastasis (p< 0.001). In all patients (n= 159), nodal SUVmax (SUVmaxN), total TLG, and thepresence of distant metastasis were independent predictors. The 2-year OS for patients with TLG ≥ 328 and TLG < 328 were 32%and 80%, respectively. Independent predictors for OS were found as SUVmaxN in the group of patients with distant metastasis, andSUVmax, MTV of the primary tumor (MTVT), and lymph node size (LNsize) in the group of patients without distant metastasis. 18F FDGPET/CT may distinguish patients with high risk for poor prognosis in patients with and without metastasis.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
2. UyBico SJ, Wu CC, Suh RD, et al. Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30: 1163-1181, 2010.
3. Ruilong Z, Daohai X, Li G, et al. Diagnostic value of 18F-FDGPET/ CT for the evaluation of solitary pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun 38: 67-75, 2017.
4. Huellner MW, de Galiza Barbosa F, Husmann L, et al. TNM staging of non–small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med 57: 21-26, 2016.
5. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50 Suppl 1: 31S-42S, 2019.
6. van den Berg LL, Klinkenberg TJ, Groen HJ, et al. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol 10: 826-831, 2015.
7. Sheikhbahaei S, Mena E, Yanamadala A, et al. The value of FDG PET/CT in treatment response assessment, follow-up, and surveillance of lung cancer. AJR Am J Roentgenol 208: 420-433, 2017.
8. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41: 1533-1541, 2005.
9. Jeong HJ, Min JJ, Park J, et al. Determination of the prognostic value of [18F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23: 865-870, 2002.
10. Imamura Y, Azuma K, Kurata S, et al. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer 71: 49-54, 2011.
11. Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 39: 27-38, 2012.
12. Agrawal V, Coroller T, Hou Y, et al. Mediastinal lymph node olvume is associated with locoregional recurrence and overall survival in stage IIIA-IIIB Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 96: E451, 2016.
13. Pöttgen C, Levegrün S, Theegarten D, et al. Value of 18Ffluoro- 2-deoxy-D-glucose-positron emission tomography/ computed tomography in non–small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12: 97-106, 2006.
14. Nwogu CE, Groman A, Fahey D, et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg 93: 1614-1620, 2012.
15. Nappi A, Gallicchio R, Simeon V, et al. [F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients. Radiol Oncol 49: 320-326, 2015.
16. Chung HW, Lee KY, Kim HJ, et al. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol 140: 89-98, 2014.
17. Zhang H, Wroblewski K, Appelbaum D, Pu Y. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer. Int J Comput Assist Radiol Surg 8: 181-191, 2013.
18. Chen HH, Chiu NT, Su WC, et al. Prognostic value of wholebody total lesion glycolysis at pretreatment FDG PET/CT in non–small cell lung cancer. Radiology 264: 559-566, 2012.
19. Ding N, Pang Z, Zhang X, et al. Prognostic and predictive effects of positive lymph node number or ratio in NSCLC. Sci Rep 7: 1-9, 2017.
20. Rice SR, Molitoris JK, Vyfhuis MA, et al. Lymph node size predicts for asymptomatic brain metastases in patients with non–small-cell lung cancer at diagnosis. Clin Lung Cancer 20: e107-e14, 2019.
21. Zhang YK, Tan Ll, Wang ZY, et al. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer. World J Surg Oncol 15: 64, 2017.
22. Okereke IC, Gangadharan SP, Kent MS, et al. Standard uptake value predicts survival in non–small cell lung cancer. Ann Thorac Surg 88: 911-916, 2009.

APA	kupik o, Bozkurt M, Asa S, Eren Kupik G, GÜNDOĞDU H, ARPA M (2020). Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. , 162 - 170. 10.4999/uhod.204173
Chicago	kupik osman,Bozkurt Mehmet,Asa Sertac,Eren Kupik Gülnihan,GÜNDOĞDU HASAN,ARPA Medeni Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. (2020): 162 - 170. 10.4999/uhod.204173
MLA	kupik osman,Bozkurt Mehmet,Asa Sertac,Eren Kupik Gülnihan,GÜNDOĞDU HASAN,ARPA Medeni Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. , 2020, ss.162 - 170. 10.4999/uhod.204173
AMA	kupik o,Bozkurt M,Asa S,Eren Kupik G,GÜNDOĞDU H,ARPA M Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. . 2020; 162 - 170. 10.4999/uhod.204173
Vancouver	kupik o,Bozkurt M,Asa S,Eren Kupik G,GÜNDOĞDU H,ARPA M Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. . 2020; 162 - 170. 10.4999/uhod.204173
IEEE	kupik o,Bozkurt M,Asa S,Eren Kupik G,GÜNDOĞDU H,ARPA M "Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?." , ss.162 - 170, 2020. 10.4999/uhod.204173
ISNAD	kupik, osman vd. "Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?". (2020), 162-170. https://doi.org/10.4999/uhod.204173

APA	kupik o, Bozkurt M, Asa S, Eren Kupik G, GÜNDOĞDU H, ARPA M (2020). Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi, 30(3), 162 - 170. 10.4999/uhod.204173
Chicago	kupik osman,Bozkurt Mehmet,Asa Sertac,Eren Kupik Gülnihan,GÜNDOĞDU HASAN,ARPA Medeni Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi 30, no.3 (2020): 162 - 170. 10.4999/uhod.204173
MLA	kupik osman,Bozkurt Mehmet,Asa Sertac,Eren Kupik Gülnihan,GÜNDOĞDU HASAN,ARPA Medeni Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi, vol.30, no.3, 2020, ss.162 - 170. 10.4999/uhod.204173
AMA	kupik o,Bozkurt M,Asa S,Eren Kupik G,GÜNDOĞDU H,ARPA M Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(3): 162 - 170. 10.4999/uhod.204173
Vancouver	kupik o,Bozkurt M,Asa S,Eren Kupik G,GÜNDOĞDU H,ARPA M Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(3): 162 - 170. 10.4999/uhod.204173
IEEE	kupik o,Bozkurt M,Asa S,Eren Kupik G,GÜNDOĞDU H,ARPA M "Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?." Uluslararası Hematoloji-Onkoloji Dergisi, 30, ss.162 - 170, 2020. 10.4999/uhod.204173
ISNAD	kupik, osman vd. "Do Volume-Based and Metabolic 18F FDG PET/CT Parameters Identify Groups at Risk for Poor Prognosis in Patients with Newly Diagnosed Metastatic and Non-Metastatic Non-Small Cell Lung Cancer?". Uluslararası Hematoloji-Onkoloji Dergisi 30/3 (2020), 162-170. https://doi.org/10.4999/uhod.204173